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Tetanus in
Injecting Drug
Users, United
Kingdom
To the Editor: The epidemiology
of tetanus in the United Kingdom
changed in 2003 when a cluster of
cases in injecting drug users (IDUs)
occurred (1,2). Before 2003, the inci-
dence of tetanus was low in the
United Kingdom, with occasional
cases predominantly in unvaccinated
elderly persons (3). The situation con-
trasted with the United States where
injecting drug use is commonly
reported among persons with tetanus
(4).
We investigated the UK cluster to
identify the source of infection and
opportunities for prevention. We
ascertained cases through statutory
and nonstatutory reporting to the
Health Protection Agency and collect-
ed additional information on IDUs for
all reported cases of tetanus since
January 1, 2003, by adapting the
existing enhanced tetanus surveil-
lance. A case was defined as mild-to-
moderate trismus and at least 1 of the
following: spasticity, dysphagia, res-
piratory embarrassment, spasms,
autonomic dysfunction, in a person
who injected drugs in the month
before symptom onset. 
Twenty-five cases were reported
from July 2003 to September 2004
(Figure). Thirteen (50%) were
women; the median age of male and
female patients was 39 and 32 years
of age, respectively (range 20–53, p =
0.1). Twenty patients were white, and
1 was Chinese (information was miss-
ing for 4). None reported travel over-
seas before becoming sick. Seventeen
of 21 patients with information
reported having injected heroin intra-
muscularly or subcutaneously (pop-
ping) or having missed veins. Most
patients (16/25) came to the hospital
with severe generalized tetanus.
Injection site infections were common
(17/19). 
Two patients died (case fatality
8%). Of 23 survivors, 2 had mild dis-
ease and 21 required intensive treat-
ment for a median of 40 days (range
24–65 in 15 cases with complete infor-
mation). Tetanus immunization status
available for 20 case-patients (based
on medical records or patient and
parental recall) indicated that only 1
patient (with severe disease) had
received the 5 doses necessary for
complete coverage. Nine patients were
never vaccinated. Twelve of 14
patients tested for tetanus immunity on
admission by a standard indirect
enzyme-linked immunosorbent assay
had antibody levels lower than the cut-
off value for protection (<0.1 IU/mL).
One patient with severe disease had a
level just above the cutoff value and 1
patient with mild disease had a protec-
tive antibody level. Clostridium tetani
was isolated from 2 patients; tetanus
toxin was detected in serum from 1
and also from another patient. Other
anaerobes, including C. novyi, C. his-
tolyticum, and C. perfringens, were
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Figure. Cases of tetanus in injecting
drug users by residence (25 cases) and
place from which heroin was supplied
(14 cases with information), United
Kingdom, July 2003–September 2004.
The large circle indicates the Liverpool
area. Squares indicate the residence of
patients for whom the origin of heroin
was not reported, open circles indicate
the residence of patients for whom the
origin of heroin was reported, and solid
circles indicate the origin of heroin.LETTERS
isolated from injection site wounds of
3 patients. A heroin sample from 1
patient was tested by polymerase chain
reaction, but no evidence of tetanus
contamination was found (J.
McLauchlin, pers. comm.). One (fatal)
case of tetanus was reported from the
Netherlands through the European
Monitoring Centre for Drugs and Drug
Addiction (L. Wiessing, pers. comm.).
Tetanus, arguably the oldest infec-
tion associated with IDU (5), can be
caused by spore contamination during
production, distribution, storage, cut-
ting, reconstitution, and injection of
drugs. The widespread distribution
and temporal clustering (1) of cases in
the United Kingdom suggest that its
cause was contamination of heroin
rather than changes in injecting prac-
tices. This finding is consistent with
results of a similar investigation of a
cluster of C.  botulinum  in IDUs in
California (6). Only 1 case was report-
ed outside the United Kingdom, which
suggests that contamination occurred
within the United Kingdom. The pro-
nounced clustering of the place from
which the heroin was supplied, com-
pared with the residence of IDUs
(Figure), is consistent with contami-
nated heroin having been distributed
from Liverpool.
Intramuscular or subcutaneous
injection of heroin was common
among case-patients. This was also
found in a large international outbreak
of C. novyi in IDUs (7) and a botulism
outbreak in IDUs in California (6),
and is consistent with the obligate
anaerobe characteristic of Clostridium
spp. In our cluster and in other out-
breaks, women and older injectors
were overrepresented compared with
demographic estimates of IDUs (8).
Women and long-term IDUs may
have difficulty accessing veins and
frequently inject intramuscularly or
subcutaneously. Furthermore, tetanus
immunity is more likely to be inade-
quate or have waned with age. 
The reasons for emergence of
Clostridium infections in IDUs in the
United Kingdom remain speculative
(9). They include an increase in con-
tamination of heroin and an aging
cohort of heroin users who are more
likely to use popping as the mode of
injection. 
In the United Kingdom, 5 doses of
tetanus toxoid–containing vaccine at
appropriate intervals are considered to
provide lifelong protection, as long as
tetanus-prone wounds are treated with
tetanus immunoglobulin (10). Only 1
case in the present cluster received the
recommended 5 doses of tetanus vac-
cine. This coverage is lower than what
might be expected. During the period
in which most of the patients were
born (1964–1984), primary immu-
nization coverage increased from
75% to 85% (www.hpa.org.uk). Since
IDUs are at risk for Clostridium infec-
tions (9), drug action teams, needle
exchange programs, prison staff, and
clinicians should ensure that IDUs are
vaccinated against tetanus and educat-
ed about signs and symptoms of soft
tissue infections that require prompt
medical intervention. 
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